ALKBH3 inhibition normalizes neovessels by reprogramming endothelial fate in diabetic microvasculopathy
Proceedings of the National Academy of Sciences · 25.08.2026 · 123 (34)
DOI: 10.1073/pnas.2602779123 ↗Kurz gefasst
Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, online erschienen am 21.08.2026. Verfasst von Yi-Chen Zhang und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, The First Affiliated Hospital of Nanjing Medical University, Nanjing Medical University, Nanjing 210029, China. Hauptthemen laut MEDLINE: Diabetic Retinopathy, AlkB Homolog 3, Alpha-Ketoglutarate-Dependent Dioxygenase, Endothelial Cells, Retinal Neovascularization. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: MOST | National Natural Science Foundation of China (NSFC), "333 Project" of Jiangsu Province ("333" Project of Jiangsu Province), Jiangsu Province Hospital High-level Talent Cultivation Program.
Abstract (Originalsprache)
Diabetic microvasculopathy is a serious diabetes complication, with diabetic retinopathy (DR) being a leading cause of blindness worldwide due to immature, leaky neovessels. Antiangiogenic therapies merely suppress neovascularization, leaving the retina oxygen-starved and prone to regrowth. Thus, therapies that stabilize aberrant neovessels are needed. We identify the RNA demethylase ALKBH3 as an epitranscriptional driver of diabetic microvasculopathy. Upregulated ALKBH3 in diabetic vascular endothelial cells promoted a pathological shift to an unstable, pro-angiogenic phenotype, disrupting blood-retinal barrier and forming immature neovessels, which impaired vision. Conversely, removing ALKBH3 protected against this. Mechanistically, ALKBH3 demethylated BMP2 mRNA to increase its stability via YTHDF2. We further developed a neovasculature-targeting nanoparticle delivering the ALKBH3 inhibitor HUHS015, which normalized retinal neovascularization by simultaneously limiting growth and promoting maturation. It acted synergistically with vascular endothelial growth factor (VEGF) blockade, suggesting potential for anti-VEGF-resistant cases. Our work defines ALKBH3 as a key mediator of diabetic microvasculopathy and supports a VEGF-independent therapeutic paradigm that shifts the focus from vessel suppression to active normalization.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Ophthalmology, The First Affiliated Hospital of Nanjing Medical University, Nanjing Medical University, Nanjing 210029, China.
- Key Laboratory for Nano-Bio Interface, Suzhou Institute of Nano-Tech and Nano-Bionics, Chinese Academy of Sciences, Suzhou 215123, China.
- Eye Institute and Department of Ophthalmology, Eye, Ear, Nose, and Throat Hospital, Fudan University, Shanghai 200031, China.
ORCID-Profile: Shi-Yao Xu, Ying Wang, Xue Chen
Förderung
- MOST | National Natural Science Foundation of China (NSFC)
- "333 Project" of Jiangsu Province ("333" Project of Jiangsu Province)
- Jiangsu Province Hospital High-level Talent Cultivation Program
- “333 Project” of Jiangsu Province
Zitieren
APA
Zhang, Y. C., Ding, Z. Q., Xu, S. Y., Chen, J. Y., Chen, M. H., Luo, B. Q., Wang, Y., Wu, Y. Y., Lv, X. Y., Liu, X. Z., Zhao, C., Liu, Q. H., & Chen, X. (2026). ALKBH3 inhibition normalizes neovessels by reprogramming endothelial fate in diabetic microvasculopathy. Proceedings of the National Academy of Sciences, 123(34). https://doi.org/10.1073/pnas.2602779123
Vancouver
Zhang YC, Ding ZQ, Xu SY, Chen JY, Chen MH, Luo BQ, et al. ALKBH3 inhibition normalizes neovessels by reprogramming endothelial fate in diabetic microvasculopathy. Proceedings of the National Academy of Sciences. 2026;123(34). doi:10.1073/pnas.2602779123
BibTeX
@article{Zhang2026,
author = {Zhang, Yi-Chen and Ding, Zi-Qin and Xu, Shi-Yao and Chen, Ji-Yu and Chen, Ming-Hui and Luo, Bing-Qing and Wang, Ying and Wu, Yan-Yi and Lv, Xin-Yao and Liu, Xing-Zhu and Zhao, Chen and Liu, Qing-Huai and Chen, Xue},
title = {ALKBH3 inhibition normalizes neovessels by reprogramming endothelial fate in diabetic microvasculopathy},
journal = {Proceedings of the National Academy of Sciences},
year = {2026},
volume = {123},
number = {34},
doi = {10.1073/pnas.2602779123}
}
EUVIMED